Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...
With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...
The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...
Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...
Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...
The Print on MSN1d
Top pharma alliance refutes ‘ill-researched’ US study linking Indian generics to higher adverse eventsIndian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback